AHB
KALV

Abner Herrman & Brock’s KalVista Pharmaceuticals KALV Stock Holding History

Abner Herrman & Brock’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,227
Closed -$113K – 112
2015
Q4 		$113K Buy
+2,227
New +$117K 0.06% 74

Other funds holding KALV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Abner Herrman & Brock's KALV Position: Q1 2016 in Review

Abner Herrman & Brock sold out of KalVista Pharmaceuticals (KALV) in Q1 2016, closing a stake of 2,227 shares — an estimated $113K sold.

Abner Herrman & Brock first reported a position in KALV in Q4 2015 and held it in 1 quarter. The position peaked at $113K in Q4 2015. 32 funds tracked by Wall St. Rank hold KALV as of Q1 2016.

  • Abner Herrman & Brock reported no remaining KalVista Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Abner Herrman & Brock sold 2,227 KalVista Pharmaceuticals shares in Q1 2016, an estimated $113K.
  • Abner Herrman & Brock first reported a position in KalVista Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Abner Herrman & Brock's KalVista Pharmaceuticals position peaked at $113K in Q4 2015.
  • 32 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2016.

Based on Abner Herrman & Brock's 13F filing for Q1 2016, filed 8 Apr 2016.